Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Recruiting · NCT04580420 · Registry updated 2025-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, primary hyperoxaluria type 1, urinary system disorder | Recruiting | Phase 2 | 2025-12-24 | NCT04580420 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||